Fintel reports that on July 29, 2025, William Blair downgraded their outlook for Neogen (NasdaqGS:NEOG) from Outperform to ...

Onvansertib combined with standard care showed up to 49% confirmed ORR in RAS-mutated colorectal cancer, with early signs of ...

Design and product development platform Figma (FIG) priced its IPO at $33 on Wednesday, which is $1 above the top end of its ...

Meta's strong earnings report sent its stock soaring after hours. The company also made it clear that the AI talent wars come ...

Vinay Prasad, M.D., has left the FDA less than three months into the role as director of the Center for Biologics Evaluation ...

But while many analysts presented a bullish case for the company's turnaround, not all investors are sold on Niccol and his ...

Data analytics firm Verisk said on Wednesday it will buy AccuLynx, which makes software for roofing contractors, for $2.35 ...

Tomorrow, July 31, 2025, Figma plans to begin trading on the New York Stock Exchange under the ticker symbol "FIG." ...

Vinay Prasad, head of the Center for Biologics Evaluation and Research (CBER) at the US Food and Drug Administration (FDA), ...

Carvana’s Q2 2025 earnings highlight record growth, profitability, and exciting expansion efforts toward achieving ambitious long-term targets.

Cardiff Oncology has reported updated results from its phase 2 colorectal cancer trial, laying out data that it believes can ...